DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
Pacira BioSciences (NASDAQ: PCRX) has announced a significant $300 million share repurchase program, receiving support from DOMA Perpetual Capital Management, which owns 4.2% of the company's outstanding shares.
The initiative, representing the largest buyback in Pacira's history, comes alongside a new emphasis on increasing pre-tax net income margins. DOMA Perpetual views these moves as reflecting Pacira's strong financial position and the Board's commitment to disciplined capital allocation.
According to Pedro Escudero, CEO of DOMA Perpetual, Pacira has entered a period of rapid growth, with scaling earnings and free cash flow enabling capital returns while maintaining investment in growth. DOMA Perpetual believes the stock is currently undervalued relative to both its historical average and future growth potential.
Pacira BioSciences (NASDAQ: PCRX) ha annunciato un programma di riacquisto azionario da 300 milioni di dollari, supportato da DOMA Perpetual Capital Management, che detiene il 4,2% delle azioni in circolazione della società.
Questa iniziativa, il più grande riacquisto nella storia di Pacira, si accompagna a un nuovo focus sull’aumento dei margini di utile netto ante imposte. DOMA Perpetual interpreta queste mosse come un segnale della solida posizione finanziaria di Pacira e dell’impegno del Consiglio di Amministrazione verso un’allocazione del capitale disciplinata.
Secondo Pedro Escudero, CEO di DOMA Perpetual, Pacira sta attraversando un periodo di rapida crescita, con utili e flussi di cassa liberi in espansione che permettono di restituire capitale agli azionisti mantenendo al contempo gli investimenti per la crescita. DOMA Perpetual ritiene che il titolo sia attualmente sottovalutato rispetto sia alla media storica sia al potenziale di crescita futura.
Pacira BioSciences (NASDAQ: PCRX) ha anunciado un programa de recompra de acciones por 300 millones de dólares, respaldado por DOMA Perpetual Capital Management, que posee el 4,2% de las acciones en circulación de la compañía.
Esta iniciativa, la recompra más grande en la historia de Pacira, se presenta junto con un nuevo enfoque en aumentar los márgenes de ingresos netos antes de impuestos. DOMA Perpetual considera que estas acciones reflejan la sólida posición financiera de Pacira y el compromiso del Consejo de Administración con una asignación disciplinada del capital.
Según Pedro Escudero, CEO de DOMA Perpetual, Pacira ha entrado en un periodo de rápido crecimiento, con ganancias y flujo de caja libre en aumento que permiten retornos de capital mientras se mantienen las inversiones en crecimiento. DOMA Perpetual cree que la acción está actualmente infravalorada en comparación con su promedio histórico y su potencial de crecimiento futuro.
Pacira BioSciences (NASDAQ: PCRX)는 3억 달러 규모의 자사주 매입 프로그램을 발표했으며, 회사 발행 주식의 4.2%를 보유한 DOMA Perpetual Capital Management의 지원을 받고 있습니다.
이번 계획은 Pacira 역사상 최대 규모의 자사주 매입으로, 법인세 차감 전 순이익률 증대에 대한 새로운 강조와 함께 진행됩니다. DOMA Perpetual은 이러한 조치가 Pacira의 견고한 재무 상태와 이사회의 엄격한 자본 배분 의지를 반영한다고 보고 있습니다.
DOMA Perpetual의 CEO 페드로 에스쿠데로에 따르면, Pacira는 급속한 성장기에 접어들었으며, 수익과 자유 현금 흐름의 확대가 성장 투자를 유지하면서도 자본 환원을 가능하게 하고 있습니다. DOMA Perpetual은 현재 주가가 역사적 평균과 미래 성장 잠재력에 비해 저평가되어 있다고 판단합니다.
Pacira BioSciences (NASDAQ : PCRX) a annoncé un programme de rachat d’actions de 300 millions de dollars, soutenu par DOMA Perpetual Capital Management, qui détient 4,2 % des actions en circulation de la société.
Cette initiative, le plus important rachat d’actions de l’histoire de Pacira, s’accompagne d’un nouvel accent mis sur l’augmentation des marges de résultat net avant impôts. DOMA Perpetual considère ces mesures comme le reflet de la solidité financière de Pacira et de l’engagement du conseil d’administration envers une allocation rigoureuse du capital.
Selon Pedro Escudero, PDG de DOMA Perpetual, Pacira entre dans une période de croissance rapide, avec des bénéfices et des flux de trésorerie disponibles en hausse permettant des retours de capitaux tout en maintenant les investissements dans la croissance. DOMA Perpetual estime que l’action est actuellement sous-évaluée par rapport à sa moyenne historique et à son potentiel de croissance futur.
Pacira BioSciences (NASDAQ: PCRX) hat ein Aktienrückkaufprogramm in Höhe von 300 Millionen US-Dollar angekündigt, das von DOMA Perpetual Capital Management unterstützt wird, welches 4,2 % der ausstehenden Aktien des Unternehmens hält.
Diese Initiative, der größte Rückkauf in der Geschichte von Pacira, geht einher mit einem neuen Fokus auf die Steigerung der Vorsteuer-Nettoeinkommensmargen. DOMA Perpetual sieht diese Maßnahmen als Ausdruck der starken finanziellen Lage von Pacira und des Engagements des Vorstands für eine disziplinierte Kapitalallokation.
Pedro Escudero, CEO von DOMA Perpetual, erklärt, dass Pacira sich in einer Phase schnellen Wachstums befindet, wobei steigende Gewinne und freier Cashflow Kapitalrückführungen ermöglichen und gleichzeitig Investitionen in Wachstum aufrechterhalten werden. DOMA Perpetual ist der Ansicht, dass die Aktie derzeit im Vergleich zu ihrem historischen Durchschnitt und ihrem zukünftigen Wachstumspotenzial unterbewertet ist.
- $300 million share repurchase program authorized - largest in company history
- Company entering period of rapid growth with scaling earnings
- Strong free cash flow generation capacity
- New focus on increasing pre-tax net income margins
- None.
Insights
Pacira's $300M buyback (26% of market cap) signals management confidence and should enhance shareholder value through improved EPS metrics.
Pacira BioSciences' newly authorized
This capital return initiative, coupled with Pacira's new emphasis on improving pre-tax net income margins, demonstrates the Board's commitment to enhancing shareholder returns. DOMA Perpetual, which holds a
From a financial perspective, the share repurchase program creates several potential benefits:
- Reduced share count leading to improved earnings per share metrics
- More efficient capital structure utilization
- Potential support for share price if the stock is indeed undervalued as DOMA suggests
DOMA Perpetual's public support indicates confidence from a significant shareholder that Pacira has entered what they describe as a period of growth with momentum in scaling earnings and free cash flow. This perspective suggests the company can simultaneously return substantial capital while continuing to invest in growth initiatives.
The effectiveness of this capital allocation strategy will ultimately depend on management's execution capabilities, both in implementing the buyback program efficiently and in delivering on the margin improvement initiatives that were also highlighted in the announcement.
DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History
Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value.
In DOMA Perpetual's view, the announced initiatives reflect Pacira's robust financial position and the Board's commitment to disciplined capital allocation. The combination of the
"After engaging in conversations with representatives of the Company's Board and management team, we are encouraged by the clear steps Pacira is taking to drive long-term value creation," said Pedro Escudero, CEO and CIO of DOMA Perpetual. "We believe Pacira has entered a period of rapid growth; the new capital allocation priorities reflect the Company's considerable momentum as it continues scaling earnings and free cash flow, enabling it to return meaningful capital to shareholders while still investing in growth. It is our conviction the stock is undervalued relative to its historical average valuation and, more importantly, relative to the multiyear cycle of growth ahead."
Contact:
DOMA Perpetual Capital Management LLC
ir@domaperpetual.com
Disclaimer
This press release has been prepared by DOMA Perpetual Management LLC and its affiliates ("DOMA Perpetual"). The views expressed herein reflect the opinions of DOMA Perpetual and are based on publicly available information with respect to Pacira BioSciences, Inc. ("Pacira" or the "Company"). DOMA Perpetual recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with DOMA Perpetual's conclusions. DOMA Perpetual reserves the right to change or modify any of such views or opinions at any time and for any reason and expressly disclaims any obligation to correct, update, or revise the information contained herein or to otherwise provide any additional materials.
For the avoidance of doubt, this press release was not produced by any person that is affiliated with Pacira, nor was its content endorsed by Pacira. This press release is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. One or more funds managed by DOMA Perpetual currently beneficially owns shares of the Company.
Some of the materials in this press release contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," "plan," "once again," "achieve," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on DOMA Perpetual's current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of DOMA Perpetual.
_______________________________
i Pacira BioSciences, Inc. https://www.globenewswire.com/news-release/2025/04/17/3063878/0/en/Pacira-BioSciences-Reaffirms-Commitment-to-Enhancing-Value-for-All-Shareholders.html
ii Pacira BioSciences, Inc. https://www.globenewswire.com/news-release/2025/04/17/3063878/0/en/Pacira-BioSciences-Reaffirms-Commitment-to-Enhancing-Value-for-All-Shareholders.html
View original content to download multimedia:https://www.prnewswire.com/news-releases/doma-perpetual-supports-paciras-new-300-million-share-repurchase-authorization-as-a-meaningful-step-to-enhance-value-for-shareholders-302433304.html
SOURCE DOMA Perpetual
FAQ
What is the size of Pacira's (PCRX) new share repurchase program?
How much of Pacira (PCRX) does DOMA Perpetual own?
What are the main objectives of Pacira's (PCRX) new capital allocation strategy?
Why does DOMA Perpetual believe Pacira (PCRX) stock is undervalued?
